Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of [14C] MGL-3196 in Healthy Males
NCT03220165Phase 1Completed
- Sponsor
- Madrigal Pharmaceuticals
- Start
- Aug 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of resmetirom in Nonalcoholic steatohepatitis (NASH), sponsored by Madrigal Pharmaceuticals. Primary endpoint: Mass Balance of [14C] MGL-3196 at 10 days. Started Aug 2017; status: completed.
02
Drugs
resmetirom
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03220165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03220165.